RMIT University
Browse

Gating Mechanism for Biased Agonism at Angiotensin II Type 1 Receptors

Download (2.46 MB)
journal contribution
posted on 2025-10-27, 03:11 authored by Graham J Moore, Harry Ridgway, Laura Kate Gadanec, Vasso ApostolopoulosVasso Apostolopoulos, Anthony Zulli, John M Matsoukas
<p dir="ltr">For the interaction of angiotensin II (AngII) with AngII type 1 receptors (AT<sub>1</sub>R), two potential proton hopping pathways have been identified, each associated with distinct physiological outcomes. The octapeptide AngII (Asp<sup>1</sup>-Arg<sup>2</sup>-Val<sup>3</sup>-Tyr<sup>4</sup>-Ile<sup>5</sup>-His<sup>6</sup>-Pro<sup>7</sup>-Phe<sup>8</sup>) appears to form a charge relay system (CRS) in solution in which the C-terminal carboxylate abstracts a proton from the His<sup>6</sup> imidazole group, which, in turn, abstracts a proton from the Tyr<sup>4</sup> hydroxyl (OH) group, creating a tyrosinate anion. When AngII binds to the AT<sub>1</sub>R, the CRS can be reconstituted with D281 of the receptor taking up the role of the Phe<sup>8</sup> carboxylate in the tripartite interaction, whilst the Phe<sup>8</sup> carboxylate forms a salt bridge with K199 of the receptor. As a consequence, the Tyr<sup>4</sup> OH of AngII is positioned with accessibility to either the Phe<sup>8</sup> carboxylate (bound to K199) or the His<sup>6</sup> imidazole (activated by D281), thereby creating a potential gating mechanism for AT<sub>1</sub>R receptor signaling. This study summarizes evidence based on structure activity data for various analogs wherein Tyr<sup>4</sup> OH interaction with His<sup>6</sup> imidazole (CRS formation) leads to G protein sequestration and vasoconstriction, whereas Tyr<sup>4</sup> OH interaction with Phe<sup>8</sup> carboxylate (bound to K199) engenders arrestin-mediated vasodilation and receptor desensitization. These findings, combined with quantum mechanical (semiempirical) calculations of CRS proton transfer presented herein, provide insights for the therapeutic targeting of angiotensin receptor blockers (sartans) and the development of second-generation drugs (bisartans).</p>

Funding

RMIT University | PH098

History

Related Materials

  1. 1.
  2. 2.
  3. 3.
    PMID - Has metadata PubMed 40509287
  4. 4.
    PMID - Has metadata PubMed PMC12156802
  5. 5.
    DOI - Is published in DOI: 10.3390/molecules30112399
  6. 6.
    ISSN - Is published in 1431-5157 (Molecules)
  7. 7.
    EISSN - Is published in 1420-3049 (Molecules)

Journal

Molecules

Volume

30

Issue

11

Total pages

24

Publisher

MDPI

Language

eng

Copyright

© 2025 by the authors.

Open access

  • Yes

Usage metrics

    Scholarly Works

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC